LP
Lucid Peptides
Research Grade

Research Summary

HMG (Human Menopausal Gonadotropin)

Research Hub
Clinical — 10 studies

HMG is a hormone preparation containing FSH and LH activity, studied in reproductive and endocrine research.

Being studied for

Gonadotropin signaling researchEndocrine axis studies

Published Research

Evidence profile

Controlled human evidence

10 cited publications · 5 primary trials

Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.

Supporting evidence

ClinicalPrimary trial

Human menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a randomized controlled trial

Li J et al. · Journal of assisted reproduction and genetics · 2025

The study reportedApplication of 5.0 mg LE followed with HMG does not improve the pregnancy rate compared to 2.5 mg LE in infertile women with PCOS. An increased dose of LE to 5.0 mg may increase the risks of OHSS and multiple pregnancies. Therapy of LE (2.

PMID 40193016DOI 10.1007/s10815-025-03455-z
View on PubMed
ClinicalPrimary trial

Subcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles

Kaplan PF et al. · American journal of obstetrics and gynecology · 2000

The study reportedSubcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination treatment cycles was generally well tolerated and yielded stimulation parameters and pregnancy rates similar to those associated with the intramuscular route.

PMID 10871458DOI 10.1067/mob.2000.106131
View on PubMed
ClinicalPrimary trial

Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization

Maroulis GB et al. · Fertility and sterility · 1991

The study reportedThese findings suggest that there is no obvious superiority between the two GnRH-a protocols in the dosage schedule used and that the major advantage of GnRH-a over non-GnRH-a protocols is in decreasing the cancellation rate and increasing the number of oocytes and conceptus obtained.

PMID 1903732DOI 10.1016/s0015-0282(16)54368-4
View on PubMed
ClinicalPrimary trial

Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression

Edelstein MC et al. · Fertility and sterility · 1990

The study reportedThere were no significant differences between hMG and FSH cycles with regard to the day of hCG administration, mean peak estradiol levels, number of ampules of medication used, and number of oocytes aspirated, embryos transferred, or pregnancies.

PMID 2104806DOI 10.1016/s0015-0282(16)53224-5
View on PubMed
ReviewSystematic review

Comparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis

Dahan MH et al. · Gynecologic and obstetric investigation · 2026

The study reportedThe higher number of oocytes retrieved with r-hFSH:r-hLH is a pertinent finding, owing to the well-established positive association between oocyte number and reproductive outcomes.

PMID 41729769DOI 10.1159/000550420
View on PubMed
ReviewSystematic review

Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation

Levi Setti PE et al. · Journal of endocrinological investigation · 2015

The study reportedRecombinant follicle-stimulating hormone treatment resulted in a higher oocytes yield per cycle than human menopausal gonadotropin at similar cost per oocyte.

PMID 25480425DOI 10.1007/s40618-014-0204-4
View on PubMed
Additional indexed literature (4)

Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.

View full peptide profile for HMG (Human Menopausal Gonadotropin)
All Research
[Notice]All information on this page is provided strictly for laboratory research and educational purposes only.